Table 4.

Cumulative incidence of common AEs reported at months 12, 24, 36, and 48 in the double-masked/open-label extension glaucoma studies with exposure 12–48 months

AE	Cumulative incidence of AEs, %
	QD bimatoprost ophthalmic solution 0.03% (n = 474)				BID bimatoprost ophthalmic solution 0.03% (n = 483)
	≤12 months	≤24 months	≤36 months	≤48 months	≤12 months	≤24 months
	Conjunctival hyperemia	45.1	45.8	46.4	46.4	56.5	57.1
Growth of eyelashes	35.4	36.5	36.5	36.7	45.5	46.6
Eye pruritus	13.9	14.3	14.6	14.8	16.1	16.4
Skin hyperpigmentation	5.7	6.1	6.3	6.3	11.8	12.2
Eye irritation	8.0	8.4	8.6	9.1	8.3	9.7
Dry eye	7.8	8.2	8.9	8.9	10.1	10.8
Hypertrichosis	8.2	8.6	8.9	8.9	9.1	9.1

Abbreviations: AE, adverse event; BID, twice daily; QD, once daily.